WuXi AppTec Co., Ltd. (SSE: 603259; HKEX: 2359), a China-based global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organisation), said on Monday it has received Frost & Sullivan's 2026 Global Company of the Year Recognition in the CRDMO industry for the tenth consecutive year.
US-based business consulting firm Frost & Sullivan highlighted WuXi AppTec's integrated CRDMO model, which enables the company to support customers across the full drug development lifecycle, from early discovery through commercial manufacturing. The firm noted WuXi AppTec's global capacity, operational consistency, and ability to adapt to increasingly complex modalities as key differentiators.
Frost & Sullivan's Company of the Year Recognition is its top honour, claiming to recognise companies that exemplify visionary innovation, market-leading performance, and unmatched customer care.
UEG introduces new Patient Representatives Advisory Board
Ionis' TRYNGOLZA recommended for EU approval in severe hypertriglyceridemia
FDA approves Genentech's Enspryng as first at-home subcutaneous treatment for thyroid eye disease
EMA issues positive CHMP opinion for Revolution Medicines' RASONQUE in metastatic pancreatic cancer
Edesa Biotech receives FDA clearance to expand EB06 vitiligo study into the US
LTR Pharma launches Roxus nasal spray for ED in the US
Galderma reports sustained symptom improvements with nemolizumab in children with atopic dermatitis
Philips-led EXIT-CVD consortium launches cardiovascular clinical studies across Europe